Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (141-150 of 315) with videos related to

Pageof 32
Sort By:
JAMA Dermatology|May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 12, 2018
Health Utility Scores of Atopic Dermatitis in US AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 18, 2019
Atopic Dermatitis in US Adults: From Population to Health Care UtilizationJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Clinical and Translational Science|August 20, 2022
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitisMohamed A Kamal, John D Davis, Pavel Kovalenko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 28, 2023
The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Toward Solutions, and Unique Considerations for Rural and Remote North American Indigenous PopulationsRachel Asiniwasis, Nickoo Merati, Jordanna Roesler, et al.
Dermatology and Therapy|January 8, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenEric L Simpson, Adelaide A Hebert, John Browning, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Journal of Dermatological Science|May 22, 2019
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)Diamant Thaçi, Eric L Simpson, Mette Deleuran, et al.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 17, 2022
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trialsPedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, et al.
Pageof 32

Showing results (141-150 of 315) with videos related to

Sort By:
Pageof 32
JAMA Dermatology|May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 12, 2018
Health Utility Scores of Atopic Dermatitis in US AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 18, 2019
Atopic Dermatitis in US Adults: From Population to Health Care UtilizationJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Clinical and Translational Science|August 20, 2022
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitisMohamed A Kamal, John D Davis, Pavel Kovalenko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 28, 2023
The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Toward Solutions, and Unique Considerations for Rural and Remote North American Indigenous PopulationsRachel Asiniwasis, Nickoo Merati, Jordanna Roesler, et al.
Dermatology and Therapy|January 8, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenEric L Simpson, Adelaide A Hebert, John Browning, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Journal of Dermatological Science|May 22, 2019
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)Diamant Thaçi, Eric L Simpson, Mette Deleuran, et al.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|June 17, 2022
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trialsPedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, et al.
Pageof 32